To accelerate the characterization of antibodies from COVID19 patients that are associated with rapid recovery compared to severe disease; and to identify potent monoclonal antibodies capable of inhibiting the virus, which will be prioritized for therapeutic development
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Amy ChungResearch Location
AustraliaLead Research Institution
University of MelbourneResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified